Mga Batayang Estadistika
| LEI | 529900FU5IIBCXYHHX25 |
| CIK | 1804591 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 23andMe Holding Co.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Chrome Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 Chrome Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| August 18, 2025 |
EX-99.1 Exhibit 99.1 UNITED STATES BANKRUPTCY COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION In re: Case No. 25-40976-357 Chapter 11 23ANDME HOLDING CO., et al.,1 Debtors. (Jointly Administered) JOINT PLAN OF CHROME HOLDING CO. AND ITS DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE PAUL, WEISS, RIFKIND, CARMODY MACDONALD P.C. WHARTON & GARRISON LLP Thomas H. Riske #61838MO P |
|
| August 18, 2025 |
EX-99.2 Exhibit 99.2 UNITED STATES BANKRUPTCY COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION In re: Case No. 25-40976-357 Chapter 11 23ANDME HOLDING CO., et al.,1 Debtors. (Jointly Administered) DISCLOSURE STATEMENT FOR THE JOINT PLAN OF CHROME HOLDING CO. AND ITS DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE PAUL, WEISS, RIFKIND, CARMODY MACDONALD P.C. WHARTON & GARRISON L |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Chrome Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2025 |
CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION 23ANDME HOLDING CO. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: FIRST: The Certificate of Incorporation of the Corporation as heretofore in effect is hereby amended such that Article I thereof shall now provi |
|
| August 4, 2025 |
exhibit22assetpurchaseag Execution Version ASSET PURCHASE AGREEMENT by and among 23ANDME HOLDING CO. |
|
| August 4, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Num |
|
| July 14, 2025 |
Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| July 14, 2025 |
Exhibit 99.1 TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets SAN FRANCISCO — July 14, 2025—TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that it has completed the acquisition of the Personal Genome Service (PGS) and Research Services busi |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| June 30, 2025 |
Exhibit 99.1 23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation SAN FRANCISCO — June 30, 2025— 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court”) for the sale |
|
| June 16, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| June 16, 2025 |
Exhibit 99.1 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process TTAM Commits to Comply with Company’s Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy |
|
| June 11, 2025 |
Exhibit 10.28 March 21, 2025 23andMe Holding Co. 870 Market Street, Room 415 San Francisco, CA 94102 Attn: Joe Selsavage Chief Financial Officer Dear Joe: This letter confirms and sets forth the terms and conditions of the engagement between Alvarez & Marsal North America, LLC (“A&M”) and 23andMe Holding Co. and its subsidiaries and their respective assigns and successors (the “Company”), includin |
|
| June 11, 2025 |
Execution Version Exhibit 10.30 FIRST AMENDMENT TO SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT TO SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT (this “Amendment”) is made as of May 6, 2025, by and among JMB CAPITAL PARTNERS LENDING, LLC, a California limited liability company (“Lender”), 23ANDME HOLDING CO., |
|
| June 11, 2025 |
Execution Version Exhibit 10.31 SECOND AMENDMENT TO SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT (this “Amendment”) is made as of June 5, 2025, by and among JMB CAPITAL PARTNERS LENDING, LLC, a California limited liability company (“Lender”), 23ANDME HOLDING C |
|
| June 11, 2025 |
Execution Version Exhibit 10.26 AGREEMENT FOR SERVICE OF INDEPENDENT DIRECTOR This Agreement for Service of Independent Director (“Agreement”), effective as of the date of the filing of a petition under title 11 of the United States Code by the Company (“Effective Date”), is made and entered into by and between 23andMe Holding Co., a Delaware corporation, with principal offices located at 870 Mark |
|
| June 11, 2025 |
Privileged & Confidential Exhibit 10.27 CASH RETENTION AGREEMENT THIS CASH RETENTION AGREEMENT (this “Agreement”) is entered into and effective as of March 21, 2025 (the “Effective Date”), by and between 23andMe, Inc. (the “Company”), and Joseph Anthony Selsavage, an employee of the Company (“Employee”). RECITALS WHEREAS, continuation of Employee’s duties is important to the Company’s ability to s |
|
| June 11, 2025 |
Execution Version Exhibit 2.5 ASSET PURCHASE AGREEMENT by and among 23ANDME HOLDING CO. and THE DIRECT AND INDIRECT SUBSIDIARIES OF 23ANDME HOLDING CO. and REGENERON PHARMACEUTICALS, INC. DATED AS OF MAY 17, 2025 TABLE OF CONTENTS Page ARTICLE I Definitions .................................................................................................................. 1 Section 1.1 Certain Defin |
|
| June 11, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39587 |
|
| June 11, 2025 |
Exhibit 21.1 23andMe Holding Co. Subsidiaries of the Registrant as of March 31, 2025 Name of Subsidiary Jurisdiction of Incorporation or Organization 23andMe, Inc. Delaware 23andMe Pharmacy Holdings, Inc. Delaware Lemonaid Health Inc. Delaware Lemonaid Pharmacy Holdings, Inc. Delaware LPharm RX LLC Delaware LPharm INS LLC Delaware LPharm CS LLC Delaware LPRXOne LLC Missouri LPRXTwo LLC Missouri LP |
|
| June 6, 2025 |
25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39587 23andMe Holding Co. Nasdaq Capital Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 870 Mark |
|
| June 3, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 As filed with the Securities and Exchange Commission on June 3, 2025 Registration No. |
|
| June 3, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 S-8 POS As filed with the Securities and Exchange Commission on June 3, 2025 Registration No. |
|
| June 3, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 As filed with the Securities and Exchange Commission on June 3, 2025 Registration No. |
|
| June 3, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 As filed with the Securities and Exchange Commission on June 3, 2025 Registration No. |
|
| June 3, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 S-8 POS As filed with the Securities and Exchange Commission on June 3, 2025 Registration No. |
|
| June 3, 2025 |
RW June 3, 2025 BY EDGAR TRANSMISSION Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: 23andMe Holding Co. |
|
| June 3, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 S-8 POS As filed with the Securities and Exchange Commission on June 3, 2025 Registration No. |
|
| June 3, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 As filed with the Securities and Exchange Commission on June 3, 2025 Registration No. |
|
| May 19, 2025 |
EXHIBIT 99.1 Press Release Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO — May 19, 2025— 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2025 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| May 2, 2025 |
Exhibit 10.1 EXECUTION VERSION SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT by and among 23ANDME HOLDING CO., THE OTHER BORROWERS PARTY HERETO and JMB CAPITAL PARTNERS LENDING, LLC as Lender Dated as of April 28, 2025 TABLE OF CONTENTS Page 1. DEFINITIONS AND CONSTRUCTION 2 1.1 Definitions 2 1.2 Accounting Terms 16 1.3 UCC 16 1.4 Construction 17 1.5 Schedule |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| March 24, 2025 |
EX-99.2 Exhibit 99.2 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support On |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2025 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| March 24, 2025 |
EX-99.1 Exhibit 99.1 Filing Subsidiaries No. Entity Name State of Incorporation 1. 23andMe Holding Co. Delaware 2. 23andMe, Inc. Delaware 3. Lemonaid Health, Inc. Delaware 4. 23andMe Pharmacy Holdings, Inc. Delaware 5. Lemonaid Pharmacy Holdings Inc. Delaware 6. Lemonaid Community Pharmacy, Inc. Missouri 7. LPharm INS LLC Delaware 8. LPharm CS LLC Delaware 9. LPharm RX LLC Delaware 10. LPRXOne LLC |
|
| February 21, 2025 |
EX-2 2 ck0001459200-ex2.htm EXHIBIT 2 - NONBINDING PROPOSAL LETTER Highly Confidential STRICTLY CONFIDENTIAL VIA EMAIL February 20, 2025 Members of the Special Committee of the Board of Directors 23andMe Holding Co. 349 Oyster Point Boulevard South San Francisco, California 94080 Dear Members of the Special Committee: Anne Wojcicki (“Ms. Wojcicki”) and New Mountain Capital L.L.C. (“New Mountain”) |
|
| February 6, 2025 |
Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of 23andMe Holding Co. (the “Company”) on Form 10-Q for the quarter ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as ado |
|
| February 6, 2025 |
Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a). Exhibit 31.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Selsavage, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of 23andMe Holding Co. for the quarter ended December 31, 2024; 2.Based on my knowledge, this report does not contain any untrue st |
|
| February 6, 2025 |
Certificate of Incorporation of 23andMe Holding Co. (as amended through October 16, 2024). /s/ Jeffrey W. Bullock /s/ JAMES CAHILLANE /s/ Jeffrey W. Bullock Anne Wojcicki Name: /s/ Anne Wojcicki By: |
|
| February 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number |
|
| February 6, 2025 |
Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a). Exhibit 31.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anne Wojcicki, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of 23andMe Holding Co. for the quarter ended December 31, 2024; 2.Based on my knowledge, this report does not contain any untrue state |
|
| February 6, 2025 |
Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the quarterly report of 23andMe Holding Co. (the “Company”) on Form 10-Q for the quarter ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as ado |
|
| January 28, 2025 |
EXHIBIT 99.1 23andMe Reports Third Quarter Fiscal Year 2025 Financial Results Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., January 28, 2025 - 23andMe Holding Co. (Nasdaq: ME) (“23andMe,” the “Company,” “we,” “us,” and “our”), a leading human genetics company with a mission to help people |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 15, 2024 |
ME / 23andMe Holding Co. / ABeeC 2.0, LLC - SCHEDULE 13D, AMENDMENT NO. 7 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q306 (CUSIP Number |
|
| November 15, 2024 |
ME / 23andMe Holding Co. / GLAXOSMITHKLINE PLC - AMENDMENT TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) * INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q3 |
|
| November 13, 2024 |
ME / 23andMe Holding Co. / Zentree Investments Ltd Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 23andMe Holding Co. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q306 (CUSIP Number) November 8, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate |
|
| November 12, 2024 |
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results EXHIBIT 99.1 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results SUNNYVALE, Calif., November. 12, 2024 - 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: •Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for th |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| October 30, 2024 |
23andMe Regains Compliance with Nasdaq Listing Requirements EX-99.1 Exhibit 99.1 23andMe Regains Compliance with Nasdaq Listing Requirements SUNNYVALE, Calif., October 30, 2024 — 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the majority inde |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 29, 2024 |
23andMe Appoints Three New Independent Directors to Board Exhibit 99.1 23andMe Appoints Three New Independent Directors to Board SUNNYVALE, Calif., October 29, 2024 — 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company’s B |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 29, 2024 |
ME / 23andMe Holding Co. / ABeeC 2.0, LLC - SCHEDULE 13D, AMENDMENT NO. 6 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q306 (CUSIP Number |
|
| October 21, 2024 |
ME / 23andMe Holding Co. / SC US (TTGP), LTD. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* 23andMe Holding Co. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class o |
|
| October 16, 2024 |
Exhibit 10.1 23ANDME HOLDING CO. SECOND AMENDED AND RESTATED 2021 INCENTIVE EQUITY PLAN Effective as of the Second Restated Effective Date (as defined below), the 23andMe Holding Co. 2021 Incentive Equity Plan (as in effect from time to time, the “Plan”) is hereby amended and restated as set forth below. The purpose of the Plan is to provide employees, certain consultants and advisors, and the non |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 16, 2024 |
Exhibit 10.2 23ANDME HOLDING CO. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN I. PURPOSE OF THE PLAN This Employee Stock Purchase Plan is intended to promote the interests of 23andMe Holding Co., a Delaware corporation formerly known as VG Acquisition Corp., (together with its successors, the “Company”) and its subsidiaries by providing eligible employees with the opportunity to acquire a pro |
|
| October 16, 2024 |
Certificate of Amendment to Certificate of Incorporation of 23andMe Holding Co. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION 23ANDME HOLDING CO. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: FIRST: The Corporation filed its Certificate of Incorporation with the Secretary of State of the State of Delaware on June 16, 2021 (the “Certif |
|
| October 16, 2024 |
23andMe Announces 1-for-20 Reverse Stock Split Exhibit 99.1 23andMe Announces 1-for-20 Reverse Stock Split SUNNYVALE, Calif., October 11, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today that the 1-for-20 reverse stock split of the Company’s Class A and Class B common stock will become effective as of 12:01 a.m. EST on October 16, 2024 (the “Effective Time”). As previously disclosed, at the |
|
| October 16, 2024 |
23andMe Announces Completion of 1-for-20 Reverse Stock Split Exhibit 99.2 23andMe Announces Completion of 1-for-20 Reverse Stock Split SUNNYVALE, Calif., October 16, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today the completion of the previously announced 1-for-20 reverse stock split of the Company’s Class A and Class B common stock and confirmed that such reverse stock split became effective as of 12: |
|
| September 30, 2024 |
ME / 23andMe Holding Co. / ABeeC 2.0, LLC - SCHEDULE 13D, AMENDMENT NO. 5 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q108 (CUSIP Number |
|
| September 18, 2024 |
ME / 23andMe Holding Co. / ABeeC 2.0, LLC - SCHEDULE 13D, AMENDMENT NO. 4 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q108 (CUSIP Number |
|
| September 18, 2024 |
Press Release, dated September 17, 2024 EX-17 EXHIBIT 17 Independent Directors of 23andMe Resign from Board September 17, 2024 SOUTH SAN FRANCISCO, Calif. |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 11, 2024 |
ME / 23andMe Holding Co. / ABeeC 2.0, LLC - SCHEDULE 13D, AMENDMENT NO. 3 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q108 (CUSIP Number |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 8, 2024 |
23andMe Reports First Quarter Fiscal 2025 Financial Results EXHIBIT 99.1 23andMe Reports First Quarter Fiscal 2025 Financial Results SOUTH SAN FRANCISCO, Calif., August 8, 2024 - 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2025 (FY25), which ended June 30, 2024. Key Results and Recent Developments •Reported total revenue of $40 million in the f |
|
| August 2, 2024 |
23andMe Special Committee responds to CEO’s take-private proposal Exhibit 99.1 23andMe Special Committee responds to CEO’s take-private proposal SOUTH SAN FRANCISCO, Calif., August 2, 2024 (GLOBE NEWSWIRE) – The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Dire |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 1, 2024 |
23andMe announces CEO’s take-private proposal EX-99.1 Exhibit 99.1 23andMe announces CEO’s take-private proposal SOUTH SAN FRANCISCO, Calif., August 1, 2024 (GLOBE NEWSWIRE) – 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has received a preliminary non-binding indication of interest from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire al |
|
| July 31, 2024 |
Special Committee of the Board of Directors Exhibit 1 CONFIDENTIAL Special Committee of the Board of Directors 23andMe Holding Co. |
|
| July 31, 2024 |
ME / 23andMe Holding Co. / ABeeC 2.0, LLC - SCHEDULE 13D, AMENDMENT NO. 2 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q 108 (CUSIP Numbe |
|
| July 16, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| June 27, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 10, 2024 |
EX-99.1 Exhibit 99.1 Investor Presentation June 2024 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe’s businesses in consumer genetics and therape |
|
| June 3, 2024 |
EX-99.1 Exhibit 99.1 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting • 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response • 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 30, 2024 |
23andMe Holding Co. Compensation Recoupment Policy EXHIBIT 97 23ANDME HOLDING CO. COMPENSATION RECOUPMENT POLICY I.Purpose The Board of Directors (“Board”) of 23andMe Holding Co. (the “Company”), based on the recommendation of its Compensation Committee (the “Committee”), has adopted this Compensation Recoupment Policy (this “Policy) to implement a mandatory clawback policy if a Restatement in compliance with the Applicable Rules (each as defined |
|
| May 30, 2024 |
23andMe Second Amended and Restated Annual Incentive Plan. EXHIBIT 10.28 23andMe Second Amended and Restated Annual Incentive Plan 1.Purpose of this Plan. This 23andMe Annual Incentive Plan is intended to attract, retain, motivate and reward Participants by providing them with the opportunity to earn annual incentive compensation under this Plan related to the Company’s performance. 2.Definitions. For purposes of this Plan, the following terms shall be de |
|
| May 30, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39587 |
|
| May 30, 2024 |
23andMe Holding Co. Second Amended and Restated Insider Trading Policy. EXHIBIT 19.1 23ANDME HOLDING CO. SECOND AMENDED AND RESTATED INSIDER TRADING POLICY Effective May 18, 2023 I.INTRODUCTION The Board of Directors (the “Board”) of 23andMe Holding Co. (together with its subsidiary, the “Company,” “we,” “us,” or “our”) has adopted this Second Amended and Restated Insider Trading Policy (this “Policy”) to establish acceptable transactions in Company securities by our |
|
| May 30, 2024 |
Exhibit 21.1 23andMe Holding Co. Subsidiaries of the Registrant as of March 31, 2024 Name of Subsidiary Jurisdiction of Incorporation or Organization 23andMe, Inc. Delaware 23andMe Pharmacy Holdings, Inc. Delaware Lemonaid Health Inc. Delaware Lemonaid Pharmacy Holdings, Inc. Delaware LPharm RX LLC Delaware LPharm INS LLC Delaware LPharm CS LLC Delaware LPRXOne LLC Missouri LPRXTwo LLC Missouri LP |
|
| May 24, 2024 |
Consulting Agreement, dated as of May 23, 2024, by and between the Company and Kathy Hibbs. EX-10.1 EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement sets forth the terms of the consultancy arrangement between the Consultant (as defined below) and 23andMe, Inc. (including its affiliates, “23andMe”), as follows: Certain Definitions: “Consultant”: Kathy Hibbs “Effective Date”: May 28, 2024 “Statement of Work” or “SOW” a. “Statement of Work” or “SOW” as used in this Agreement sha |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 23, 2024 |
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results EXHIBIT 99.1 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 23, 2024 - 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments •On March 28, 2024 |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 18, 2024 |
23andMe announces CEO’s intention to pursue a potential take-private Exhibit 99.1 23andMe announces CEO’s intention to pursue a potential take-private SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) – 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acqu |
|
| April 17, 2024 |
ME / 23andMe Holding Co. / ABeeC 2.0, LLC - SCHEDULE 13D, AMENDMENT NO. 1 Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q 108 (CUSIP Numbe |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 22, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) 23andMe Holding Co. |
|
| March 22, 2024 |
As filed with the Securities and Exchange Commission on March 22, 2024 S-8 As filed with the Securities and Exchange Commission on March 22, 2024 Registration No. |
|
| February 13, 2024 |
ME / 23andMe Holding Co. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: 23andMe Holding Co. Class A Title of Class of Securities: Common Stock CUSIP Number: 90138Q108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2024 |
GB:HLN / Haleon plc / GLAXOSMITHKLINE PLC - AMENDMENT TO SC 13D Activist Investment SC 13D/A 1 gsksc13da-020924.htm AMENDMENT TO SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) * INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0 |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number |
|
| February 7, 2024 |
EXHIBIT 99.1 23andMe Reports Third Quarter Fiscal 2024 Financial Results Announced new non-exclusive data license with GSK, introduced 23andMe Total HealthTM, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 SOUTH SAN FRANCISCO, Calif., February 7, 2024 - 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported it |
|
| January 31, 2024 |
EXHIBIT 99.1 23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 ●23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells ●‘1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6, and inducing Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhance |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 8, 2024 |
January 2024 23andMe Therapeutics EXHIBIT 99.2 2Copyright © 2024 23andMe, Inc. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe’s businesses in consumer genet |
|
| January 8, 2024 |
exhibit99123andmeinvest Investor Presentation January 2024 EXHIBIT 99.1 2 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe’s businesses in consumer |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorpora |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 8, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 8, 2023 |
Exhibit 10.3 February 20, 2020 Dear William: 23andMe, Inc. (the "Company") is pleased to offer to you employment on the following terms: 1. Position. Your initial title will be Director, Target and Drug Discovery, and you will initially report to Astrid Ruefli-Brasse, Vice President, Drug Discovery. This is a full-time exempt position. By signing this offer letter agreement, you confirm with the C |
|
| November 8, 2023 |
CONFIDENTIAL Execution Copy Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. THIRD AMENDMENT TO COLLABORATION AGREEMENT This THIRD AMENDMENT TO COLLABORATION AGREEMENT (this “T |
|
| November 8, 2023 |
EXHIBIT 99.1 23andMe Reports Second Quarter Fiscal 2024 Financial Results Announced launch of new 23andMe+ Total Health™membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin SOUTH SAN FRANCISCO, Calif., November 8, 2023 - 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results |
|
| November 6, 2023 |
Exhibit 99.1 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 • 23andMe presented data from the now completed dose escalation phase, and pharmacokinetic / pharmacodynamic (PK/PD) cohorts at the Society for Immunotherapy of Cancer Annual Meeting 2023 • Dosing with 23ME-00610 monotherapy in 28 patien |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 30, 2023 |
Exhibit 99.1 PRESS RELEASE 23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe database for novel drug target discovery and other research SOUTH SAN FRANCISCO, Calif |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| October 27, 2023 |
Letter Agreement, by and between 23andMe, Inc. and Paul Johnson, dated as of October 24, 2023 EXHIBIT 10.1 October 24, 2023 Paul Johnson 317 Orchid Avenue Newport Beach, CA 92625 Re: Resignation Agreement Dear Paul: This letter (the “Agreement”) confirms the agreement between you and 23andMe, Inc. (the “Company”) regarding your resignation from the Company and the transition of your employment responsibilities with the Company. Except as set forth in this Agreement, the Company does not ow |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 15, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) 23andMe Holding Co. |
|
| September 15, 2023 |
As filed with the Securities and Exchange Commission on September 15, 2023 S-8 As filed with the Securities and Exchange Commission on September 15, 2023 Registration No. |
|
| September 15, 2023 |
Exhibit 99.1 23ANDME HOLDING CO. AMENDED AND RESTATED 2021 INCENTIVE EQUITY PLAN Effective as of the Restated Effective Date (as defined below), the 23andMe Holding Co. 2021 Incentive Equity Plan (as in effect from time to time, the “Plan”) is hereby amended and restated as set forth below. The purpose of the Plan is to provide employees, certain consultants and advisors, and the non-employee memb |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission F |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 1, 2023 |
EXHIBIT 99.1 23andMe Granted New FDA Clearance to Report Additional BRCA Variants 510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these additional variants occur more often in people of African American and Hispanic/Latino descent 23andMe also granted an FDA P |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2023 |
EXHIBIT 99.1 23andMe Reports FY2024 First Quarter Financial Results Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., August 8, 2023 - 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the |
|
| August 8, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| July 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| July 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 25, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39587 |
|
| May 25, 2023 |
Exhibit 10.16 Amendment No. 4 to Consulting Agreement and Statement of Work #1 This Amendment No. 4 (“Amendment No. 4”) is to the Consulting Agreement by and between 23andMe, Inc. (“23andMe”) and Richard Scheller, Ph.D. (“Consultant”) with an Effective Date of April 1, 2019, and as amended (“Agreement”), including Statement of Work #1 (“SOW#1”) to the Agreement. Collectively, 23andMe and Consultan |
|
| May 25, 2023 |
Relinquishment Agreement, by and between 23andMe Holding Co. and Paul Johnson, October 21, 2021. Exhibit 10.28 RELINQUISHMENT AGREEMENT This RELINQUISHMENT AGREEMENT (this “Agreement”) is made and entered into as of October 21, 2021, by and between 23andMe Holding Co., a Delaware corporation (“Parent”), and Paul Johnson (“Holder”). RECITALS A. Concurrent with the execution and delivery of this Agreement, Parent, Life Merger Sub One, Inc., a Delaware corporation and a wholly owned subsidiary o |
|
| May 25, 2023 |
Exhibit 10.32 Employee Form [ ] 23ANDME HOLDING CO. 2021 INCENTIVE EQUITY PLAN RESTRICTED STOCK UNIT AGREEMENT This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”), dated as of [ ] (the “Date of Grant”), is delivered by 23andMe Holding Co. (the “Company”) to [ ] (the “Participant”). RECITALS The 23andMe Holding Co. 2021 Incentive Equity Plan (the “Plan”) provides for the grant of restricted stoc |
|
| May 25, 2023 |
23andMe Amended and Restated Annual Incentive Plan Exhibit 10.30 23andMe Amended and Restated Annual Incentive Plan 1. Purpose of this Plan. This 23andMe Annual Incentive Plan is intended to attract, retain, motivate and reward Participants by providing them with the opportunity to earn annual incentive compensation under this Plan related to the Company’s performance. 2. Definitions. For purposes of this Plan, the following terms shall be defined |
|
| May 25, 2023 |
Exhibit 10.15 Amendment No. 3 to Consulting Agreement and Statement of Work #1 This Amendment No. 3 (“Amendment No. 3”) is to the Consulting Agreement by and between 23andMe, Inc. (“23andMe”) and Richard Scheller, Ph.D. (“Consultant”) with an Effective Date of April 1, 2019, and as amended (“Agreement”), including Statement of Work #1 (“SOW#1”) to the Agreement. Collectively, 23andMe and Consultan |
|
| May 25, 2023 |
EXHIBIT 99.1 23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 - 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people acces |
|
| May 25, 2023 |
Exhibit 21.1 23andMe Holding Co. Subsidiaries of the Registrant as of March 31, 2023 Name of Subsidiary Jurisdiction of Incorporation or Organization 23andMe, Inc. Delaware Lemonaid Health Inc. Delaware Lemonaid Health Limited United Kingdom |
|
| May 25, 2023 |
Exhibit 10.31 Non-Employee Director Form [ ] 23ANDME HOLDING CO. 2021 INCENTIVE EQUITY PLAN RESTRICTED STOCK UNIT AGREEMENT This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”), dated as of [ ] (the “Date of Grant”), is delivered by 23andMe Holding Co. (the “Company”) to [ ] (the “Participant”). RECITALS The 23andMe Holding Co. 2021 Incentive Equity Plan (the “Plan”) provides for the grant of re |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 17, 2023 |
Investor Presentation Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. |
|
| April 14, 2023 |
EXHIBIT 99.1 23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 ● First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid ma |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 3, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) 23andMe Holding Co. |
|
| March 3, 2023 |
Power of Attorney (included in the signature page to this Registration Statement). S-8 As filed with the Securities and Exchange Commission on March 3, 2023 Registration No. |
|
| March 2, 2023 |
Up to $150,000,000 Class A Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| March 2, 2023 |
Up to $500,000,000 Common Stock Preferred Stock Debt Securities 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| February 27, 2023 |
23andMe Holding Co. 349 Oyster Point Boulevard South San Francisco, CA, 94080 February 27, 2023 CORRESP 23andMe Holding Co. 349 Oyster Point Boulevard South San Francisco, CA, 94080 February 27, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Daniel Crawford Re: 23andMe Holding Co. — Registration Statement on Form S-3 (File No. 333-269595) (the “Registration Statement”) Dear Mr. Crawford: Pursu |
|
| February 14, 2023 |
ME / 23andMe Holding Co. Class A / NewView Capital Fund I, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* 23andMe Holding Co. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 90138Q108 (CUSIP Number) December 31, 2022 (Date |
|
| February 9, 2023 |
ME / 23andMe Holding Co. Class A / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: 23andMe Holding Co. Class A Title of Class of Securities: Common Stock CUSIP Number: 90138Q108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1( |
|
| February 8, 2023 |
EXHIBIT 99.1 23andMe Reports FY2023 Third Quarter Financial Results Third quarter revenue grew 18% to $67 million Consumer revenue grew 17% year over year FY2023 financial guidance raised to expected revenue range of $290 to $300 million SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) - 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company w |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number |
|
| February 6, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) 23andMe Holding Co. |
|
| February 6, 2023 |
As filed with the Securities and Exchange Commission on February 6, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on February 6, 2023 Registration Statement No. |
|
| February 6, 2023 |
EX-1.2 Exhibit 1.2 23ANDME HOLDING CO. $150,000,000 COMMON STOCK SALES AGREEMENT February 6, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: 23andMe Holding Co. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the t |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) * INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q 1 |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| December 9, 2022 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF 23ANDME HOLDING CO. ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of 23andMe Holding Co. (the ?Corporation?) within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporation?s r |
|
| December 9, 2022 |
Exhibit 10.1 23ANDME HOLDING CO. CHANGE IN CONTROL SEPARATION PLAN Introduction The Board of Directors (the ?Board?) of 23andMe Holding Co. (the ?Company?) recognizes that the Company, as a publicly held company, may experience a Change in Control (as hereinafter defined), and that the possibility of a Change in Control may create uncertainty resulting in the loss or distraction of certain key emp |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2022 |
Investor Presentation November 2022 Investor Presentation November 2022 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2022 |
EXHIBIT 99.1 23andMe Reports FY2023 Second Quarter Financial Results Second quarter revenue grew 37% to $76 million Consumer revenue grew 27% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance South San Francisco, Calif., November 7, 2022 - 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a |
|
| November 7, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 17 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update an |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 (October 7, 2022) 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 23ANDME HOLDING CO. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q 108 (CUSIP Number) V |
|
| November 4, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 16 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update an |
|
| November 3, 2022 |
As filed with the Securities and Exchange Commission on November 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on November 3, 2022 Registration No. |
|
| October 27, 2022 |
EX-99.1 Exhibit 99.1 23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for confirmatory testing of the 23andMe result SOUTH SAN FRANCISCO, C |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| September 1, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 15 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update an |
|
| September 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 30, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 14 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update an |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporat |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 19, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 13 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update an |
|
| August 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 18, 2022 |
Investor Presentation August 2022 Investor Presentation August 2022 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe?s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. |
|
| August 17, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 12 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update an |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission Fi |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39587 23ANDME HOL |
|
| August 9, 2022 |
Morgan, Lewis & Bockius llp 101 Park Avenue New York, NY 10178-0060 +1.212.309.6000 United States +1.212.309.6001 August 9, 2022 VIA EDGAR Ms. Tracey Houser Mr. Al Pavot United States Securities and Exchange Commission Division of Corporation Finance Office of Life Science 100 F Street, NE Washington, D.C. 20549 Re: 23andMe Holding Co. Form 10-K for Fiscal Year Ended March 31, 2022 Filed May 27, 2 |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2022 |
EXHIBIT 99.1 23andMe Reports FY2023 First Quarter Financial Results First quarter revenue grew 9% to $64.5 million Consumer revenue grew 17% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance South San Francisco, Calif., August 8, 2022 - 23andMe Holding Co. (Nasdaq: ME) (?23andMe?), a leading consumer genetics and research company with a mission |
|
| July 15, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 15, 2022 |
As filed with the Securities and Exchange Commission on June 15, 2022 As filed with the Securities and Exchange Commission on June 15, 2022 Registration No. |
|
| June 15, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) 23andMe Holding Co. |
|
| June 14, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 11 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update an |
|
| June 13, 2022 |
EXHIBIT 10.1 23andMe Annual Incentive Plan 1. Purpose of this Plan. This 23andMe Annual Incentive Plan is intended to attract, retain, motivate and reward Participants by providing them with the opportunity to earn annual incentive compensation under this Plan related to the Company?s performance. 2. Definitions. For purposes of this Plan, the following terms shall be defined as follows: (a) ?Affi |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39587 |
|
| May 27, 2022 |
Exhibit 21.1 23andMe Holding Co. Subsidiaries of the Registrant as of March 31, 2022 Name of Subsidiary Jurisdiction of Incorporation or Organization 23andMe, Inc. Delaware Lemonaid Health Inc. Delaware Lemonaid Health Limited United Kingdom |
|
| May 27, 2022 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of 23andMe Holding Co. (the ?Company,? ?we,? ?us,? and ?our?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF CAPITAL STOCK The fo |
|
| May 27, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 10 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being |
|
| May 26, 2022 |
EXHIBIT 99.1 23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results Achieved FY2022 financial guidance Fourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectively New genomic health services expected in FY2023 Webcast today, May 26, 2022, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 26, 2022 - |
|
| May 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 14, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 9 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update and |
|
| April 13, 2022 |
Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 23, 2022 |
Investor Presentation February 2022 Exhibit 99.1 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe?s businesses in consumer genetics and therapeutic |
|
| February 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 14, 2022 |
ME / 23andMe Holding Co. Class A / CITADEL ADVISORS LLC - 23ANDME HOLDING CO. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* 23Andme Holding Co. (Name of Issuer) Class A common stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 90138Q |
|
| February 14, 2022 |
ME / 23andMe Holding Co. Class A / MARSHALL WACE, LLP - 23ANDME HOLDING CO. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* 23andMe Holding Co. (f/k/a VG Acquisition Corp.) (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 90138Q108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 11, 2022 |
Offer Letter, dated as of October 21, 2021, by and between 23andMe Holding Co. and Paul Johnson. Employee Form EXHIBIT 10.1 October 21, 2021 Paul Johnson Dear Paul: 23andMe Holding Co. (together with its subsidiary, 23andMe, Inc., the "Company") is pleased to offer to you the following employment terms: 1. Commencement of Employment. As you know, Lemonaid Health, Inc., a Delaware corporation ("Lemonaid") has agreed to be acquired by the Company, which transaction is referred to herein as the |
|
| February 11, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 8 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update and |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39587 23ANDME |
|
| February 10, 2022 |
EXHIBIT 99.1 23andMe Reports FY2022 Third Quarter Financial Results Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of people to live healthier lives SUNNYVALE, Calif., February 10, 2022 - 23andMe Holding Co. (Nasdaq: ME) (?23andMe?), a leading consu |
|
| February 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 18, 2022 |
23andMe R&D Day January 18, 2022 Exhibit 99.1 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe?s businesses in consumer genetics and therapeutics a |
|
| January 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| January 18, 2022 |
Exhibit 99.2 23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe?s proprietary genetic and health survey database 23andMe elects for royalty option as GSK advances immuno-oncology antibody collaboration program targeting |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| January 10, 2022 |
Exhibit 99.1 23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation SUNNYVALE, CA - January 10, 2022 - 23andMe Holding Co. (Nasdaq: ME) (?23andMe?), a leading con |
|
| January 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 6, 2022 |
Exhibit 99.1 23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors 23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe?s proprietary genetic and health survey database Company will host a virtual R&D Day event on January 18, 2022 |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39587 23ANDME HOLDING CO. (Exact name of registrant as specified in its |
|
| December 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2021 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| December 28, 2021 |
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants Exhibit 99.1 23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants SUNNYVALE, Calif., December 28, 2021 ? 23andMe Holding Co. (Nasdaq: ME) (?23andMe?), a leading consumer genetics and research company, today announced the results of the completed redemption (the ?Redemption?) of all of its outstanding warrants (the ?Warrants?) to purchase shares of Class A common st |
|
| December 28, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 7 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update and |
|
| November 22, 2021 |
NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 90138Q 116) EX-99.2 3 d235266dex992.htm EX-99.2 Exhibit 99.2 November 22, 2021 NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 90138Q 116) Dear Warrant Holder, 23andMe Holding Co. (the “Company”) hereby gives notice that it is redeeming, at 5:00 p.m. New York City time on December 22, 2021 (the “Redemption Date”), all of the Company’s outstanding warrants (the “Warrants”) to purchase shares of the Com |
|
| November 22, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 6 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update and |
|
| November 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 23andMe Holding Co. (Exact name of registrant as specified in its charter) Delaware 001-39587 87-1240344 (State or other jurisdiction of incorporation) (Commission File |
|
| November 22, 2021 |
23andMe Announces Redemption of All Outstanding Warrants Exhibit 99.1 23andMe Announces Redemption of All Outstanding Warrants SUNNYVALE, Calif., November 22, 2021 ? 23andMe Holding Co. (Nasdaq: ME) (?23andMe?), a leading consumer genetics and research company, today announced that it will redeem all of its outstanding warrants (the ?Public Warrants?) to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dat |
|
| November 10, 2021 |
EX-99.1 2 me-ex991.htm EX-99.1 EXHIBIT 99.1 Press Release 23andMe Reports FY2022 Second Quarter Financial Results Second quarter revenue of $55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE, Calif., November 10, 2021 – 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer |
|
| November 10, 2021 |
Form of 23andMe Holding Co. 2021 Restricted Stock Unit Agreement (Non-Employee Director) Non-Employee Director Form EXHIBIT 10.2 23ANDME HOLDING CO. 2021 INCENTIVE EQUITY PLAN RESTRICTED STOCK UNIT AGREEMENT This RESTRICTED STOCK UNIT AGREEMENT (the ?Agreement?), dated as of [?] (the ?Date of Grant?), is delivered by 23andMe Holding Co. (the ?Company?) to [?] (the ?Participant?). RECITALS The 23andMe Holding Co. 2021 Incentive Equity Plan (the ?Plan?) provides for the grant of restric |
|
| November 10, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-257768 Prospectus Supplement No. 5 (to Prospectus dated July 15, 2021) 23andMe Holding Co. 280,940,853 Shares of Class A Common Stock 467,670 Shares of Class A Common Stock Up to 25,065,665 Shares of Class A Common Stock Issuable Upon Exercise of Warrants Up to 8,113,999 Warrants This prospectus supplement is being filed to update and |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39587 23ANDM |
|
| November 10, 2021 |
Employee Form EXHIBIT 10.1 23ANDME HOLDING CO. 2021 INCENTIVE EQUITY PLAN RESTRICTED STOCK UNIT AGREEMENT This RESTRICTED STOCK UNIT AGREEMENT (the ?Agreement?), dated as of [?] (the ?Date of Grant?), is delivered by 23andMe Holding Co. (the ?Company?) to [?] (the ?Participant?). RECITALS The 23andMe Holding Co. 2021 Incentive Equity Plan (the ?Plan?) provides for the grant of restricted stock uni |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2021 23andMe Holding Co. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39587 87-1240344 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 9, 2021 |
23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors EXHIBIT 99.1 23andMe Announces Appointment of Dr. Sandra Hern?ndez to Board of Directors Sunnyvale, Calif. ? November 9, 2021 ? 23andMe Holding Co. (Nasdaq: ME) (?23andMe?), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hern?ndez, President & CEO of the California Health Care Foundation (?CHCF?), to its Board of Directors. ?Dr. Hern?ndez is a passi |
